Electronic System Reminds Patients to Schedule Exams

News
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

A computerized mail and phone reminder program managed by appointment secretaries significantly increased the percentage of patients undergoing annual mammography at the Mayo Clinic

ROCHESTER, Minnesota—A computerized mail and phone reminder program managed by appointment secretaries significantly increased the percentage of patients undergoing annual mammography at the Mayo Clinic, according to a study by Rajeev Chaudhry, MBBS, MPH, and colleagues (Arch Intern Med 167:606-611, 2007).

The researchers randomized 6,665 women age 40 to 75 to usual care or to an intervention group that received mailings (two monthly letters starting 3 months before they were due for screening) followed by a phone call to nonresponding patients, to remind them to schedule a mammogram.

Among the reminded group, 64.3% had their annual mammogram vs 55.3% of controls (P < .001). There were no significant differences between the two groups for any of the other adult preventive services. A subgroup that also received an email reminder had a 72.2% compliance rate. As the program has expanded following the study period, compliance has now grown to more than 72%, Dr. Chaudhry said, with 86% having had one exam within the previous 2 years.

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.